Maze Therapeutics, Inc. 4

Maze Therapeutics CSBO Atul Dandekar exercised options for 7,500 shares of common stock at $10.42 and sold 7,500 shares at a weighted average of $27.5765 on August 28, 2026 under a Rule 10b5-1 plan.

On August 28, 2026, Maze Therapeutics, Inc. CSBO Atul Dandekar exercised a stock option for 7,500 shares of common stock at $10.42 per share and immediately sold the same 7,500 shares in a Rule 10b5-1 plan trade at a weighted average price of $27.5765, realizing an implied spread of roughly $17.16 per share. The option exercise was reported as acquiring 7,500 shares and increasing his direct common stock holdings to 33,750 shares, while the sale reduced his direct holdings to 26,250 shares; an additional line indicates 7,500 shares of common stock underlying options remaining (with 14,143 common shares held directly) as of the option line’s ownership table. The transaction reflects a routine, fully vested option exercise-and-sell sequence rather than an open-market purchase or discretionary large sale.

Filing Facts

CIK

1842295

Ticker

MAZE

Form

4

Source Type

fda

Accession

0002050167-26-000023

Alert Tier

5